These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1030 related articles for article (PubMed ID: 26933765)

  • 1. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
    Eskander RN; Tewari KS
    Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
    Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
    Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
    Jackson AL; Eisenhauer EL; Herzog TJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
    Monk BJ; Pujade-Lauraine E; Burger RA
    Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapies in epithelial ovarian cancer.
    Teoh DG; Secord AA
    Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.
    Gadducci A; Lanfredini N; Sergiampietri C
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):113-28. PubMed ID: 26126494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibitors for the treatment of ovarian cancer.
    Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
    Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.
    Secord AA; Nixon AB; Hurwitz HI
    Gynecol Oncol; 2014 Nov; 135(2):349-58. PubMed ID: 25178997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
    Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
    González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic drugs in the treatment of advanced epithelial ovarian cancer.
    Khosravi-Shahi P; Cabezon-Gutierrez L
    Anticancer Agents Med Chem; 2012 Oct; 12(8):982-7. PubMed ID: 22263801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Wang X; Zhu Q; Lin Y; Wu L; Wu X; Wang K; He Q; Xu C; Wan X; Wang X
    Br J Cancer; 2017 Oct; 117(9):1371-1382. PubMed ID: 28898232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
    Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis as a target for the treatment of ovarian cancer.
    Shaw D; Clamp A; Jayson GC
    Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial ovarian cancer: focus on targeted therapy.
    Pliarchopoulou K; Pectasides D
    Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.